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Background: The GBGT1 gene encodes the globoside alpha-1,3-N-acetylgalactosaminyltransferase 1. This enzyme
catalyzes the last step in the multi-step biosynthesis of the Forssman (Fs) antigen, a pentaglycosyl ceramide of the
globo series glycosphingolipids. While differential GBGT1 mRNA expression has been observed in a variety of human
tissues being highest in placenta and ovary, the expression of GBGT1 and the genes encoding the glycosyltransferases
and glycosidases involved in the biosynthesis of Fs as well as the possible involvement of DNA methylation in
transcriptional regulation of GBGT1 expression have not yet been investigated.
Results: RT-qPCR profiling showed high GBGT1 expression in normal ovary surface epithelial (HOSE) cell lines and low
GBGT1 expression in all (e.g. A2780, SKOV3) except one (OVCAR3) investigated ovarian cancer cell lines, a finding that was
confirmed by Western blot analysis. Hierarchical cluster analysis showed that GBGT1 was even the most variably expressed
gene of Fs biosynthesis-relevant glycogenes and among the investigated cell lines, whereas NAGA which encodes the
alpha-N-acetylgalactosaminidase hydrolyzing Fs was not differentially expressed. Bisulfite- and COBRA-analysis of the
CpG island methylation status in the GBGT1 promoter region demonstrated high or intermediate levels of GBGT1 DNA
methylation in all ovarian cancer cell lines (except for OVCAR3) but marginal levels of DNA methylation in the two
HOSE cell lines. The extent of DNA methylation inversely correlated with GBGT1 mRNA and protein expression.
Bioinformatic analysis of GBGT1 in The Cancer Genome Atlas ovarian cancer dataset demonstrated that this inverse
correlation was also found in primary ovarian cancer tissue samples confirming our cell line-based findings.
Restoration of GBGT1 mRNA and protein expression in low GBGT1-expressing A2780 cells was achieved by
5-aza-2’-deoxycytidine treatment and these treated cells exhibited increased helix pomatia agglutinin-staining,
reflecting the elevated presence of Fs disaccharide on these cells.
Conclusions: GBGT1 expression is epigenetically silenced through promoter hypermethylation in ovarian cancer.
Our findings not only suggest an involvement of DNA methylation in the synthesis of Fs antigen but may also
explain earlier studies showing differential GBGT1 expression in various human tissue samples and disease stages.
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The GBGT1 gene was first described in canine kidney cells
by Haslam et al. in 1996 [1] and three years later cloned in
human [2]. GBGT1 mRNA expression has been observed
in a broad variety of human tissues including small and
large intestines, placenta, and ovary [2]. GBGT1 encodes
the Forssman synthetase (globoside alpha-1,3-N-acetylga-
lactosaminyltransferase 1). Although differential methyla-
tion of GBGT1 has been associated with inflammatory
bowel disease [3] and GBGT1 nonsense and inactivating
missense mutations have been identified that produce a
truncated or enzymatically inactive enzyme [4], it is not
understood how GBGT1 expression is regulated.
Forssman synthetase catalyzes the last step in the bio-
synthesis of Forssman (Fs) antigen that involves a series
of sequential attachments of monosaccharides catalyzed
by the glycosyltransferase UGCG, B4GALT6, A4GALT,
B3GALNT1, and finally GBGT1 (Figure 1A). However,
it is unknown how and to what extent the expression
levels of not only each one of these glycosyltransferases
but also of the respective glycosidases such as NAGA
(alpha-N-acetylgalactosaminidase; hydrolyses Fs antigen)
affect the biosynthesis of Fs antigen in the cells. Like-
wise, it has not yet been investigated whether the expres-
sion levels of these glycosyltransferases and glycosidases
differ between cancer and normal cells.
Fs antigen is a pentaglycosyl ceramide (GalNAcα1-
3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer) terminated
by GalNAc and belongs to the globo series of glycosphin-
golipids (GSL). GSL comprise a heterogeneous group of
membrane lipids formed by a ceramide (Cer) backbone co-
valently linked to a glycan moiety: either galactose or
glucose to form galactosylceramide (GalCer) or gluco-
sylceramide (GlcCer), respectively. GlcCer is the precur-
sor of at least four different series of GSL. Among those
are the globo series GSL which play roles in various bio-
logical processes: they are present within lipid raft micro-
domains [5], they associate with multidrug resistance [6],
with angiogenesis [7], and with malignant diseases [8,9],
with proliferation [10]. and serve as receptors for human
pathogens [11]. Only recently, naturally occurring anti-
glycan antibodies against globo series GSL have been
identified the levels of which were lower in the plasma of
ovarian cancer patients compared to healthy women
[9,12,13], an observation that allows discriminating can-
cer patients from healthy women.
The appearance of Fs antigen is controversial. It was
thought to be absent in humans and to be expressed ex-
clusively on animal red blood cells [14]. This is in con-
trast to studies demonstrating that Fs antigen is present
in human cancer [15,16]. Svensson and colleagues found
the Fs GSL expressed also on human erythrocytes [17].
In the present study we (i) profiled a panel of ovarian
cancer and normal ovary surface epithelial cell lines forthe expression of GBGT1, NAGA, and the other glyco-
genes encoding the glycosyltransferases and glycosidases
involved in the biosynthesis of Fs, (ii) investigated whether
GBGT1 expression is regulated through DNA methylation
and whether the degree of DNA methylation correlates
with GBGT1 expression in cell lines and tissue, and (iii)
determined whether GBGT1 expression is an outcome
predictor in ovarian cancer.
Our results show that GBGT1 is the most variably
expressed gene among the Fs-relevant glycogenes and
among the investigated cell lines, DNA methylation is
involved in the regulation of GBGT1 expression in ovar-
ian cancer cell lines and tissue, and GBGT1 expression
does not predict survival.
Results
Differential expression of Forssman antigen biosynthesis-
relevant glycogenes in ovarian cell lines
We investigated whether the expression level of GBGT1
differs between ovarian cancer and normal ovarian sur-
face epithelial cells. Because the biosynthesis of Fs anti-
gen requires multiple glycan-processing enzymes, this
investigation also includes the glycogenes encoding the
corresponding glycosyltransferases and glycosidases.
The biosynthesis pathway of Fs pentasaccharide is out-
lined in Figure 1A. To this aim we profiled the transcrip-
tional activity of these 11 genes in a panel of ovarian
cancer cell lines (TOV112D, TOV21G, OVCAR3, SKOV3,
A2780, IGROV1) and normal ovarian surface epithelium
cell lines (HOSE6-3, HOSE17-1) using RT-qPCR in con-
cordance with MIQE guidelines [18].
The hierarchical cluster analysis of the ΔCq values for
each glycogene, portrayed as a heat map, produced two
branches (Figure 1B). One branch clustered eight genes
(NAGA, B4GALT6, HEXA, GLB1, GBA, GLA, UGCG,
HEXB) with generally comparable expression levels among
the cell lines, except for the UGCG gene which was
expressed at considerably higher levels in both HOSE cell
lines compared with the ovarian cancer cell lines. The
other branch clustered three genes (B3GALNT1, A4GALT,
and GBGT1) with a wide variation in gene expression
levels among the cell lines tested. B3GALNT1 was lowest
expressed in TOV112D cells (ΔCq = 17.8), moderately in
IGROV1 (ΔCq = 12.9), and highly expressed in the
remaining cell lines (ΔCq ranging from 5.5-9.9). A4GALT
was generally expressed at high levels in all the cell lines
(ΔCq ranging from 5.62-9.54), except for A2780 (ΔCq =
11.98). GBGT1 was highly expressed in both HOSE cell
lines (HOSE6-3 ΔCq = 8.86; HOSE17-1 ΔCq = 8.00)
and in the OVCAR3 ovarian cancer cell line (ΔCq =
8.74) but expressed at low levels in the remaining cell
lines (ΔCqs ranging from 14.44-14.99). Cluster analysis
also demonstrated that GBGT1 branched first in the




Figure 1 Expression of glycosyltransferase and glycosidase genes (glycogenes) involved in the biosynthesis of Fs antigen.
(A) Schematic presentation of the biosynthesis pathway of Fs pentasaccharide glycosphingolipid from glycosylceramide and of the responsible
glycosyltransferases (downward arrows) and glycosidases (upward arrows): 1. glycosylceramide; 2. lactosylceramide; 3. globotriaosylceramide (Gb3, Pk); 4.
globoside (P antigen, Gb4); 5. Forssman (Fs, IV3GalNAcα-Gb4Cer). Filled circles (glucose, Glc); open circles (galactose, Gal); squares (N-acetylgalactosamine,
GalNAc). B) Heat map with the color key representing normalized (ΔCq) and clustering of glycogene expression (rows) among the investigated
cell lines (columns). Color key indicates relative level of expression from high (white) to low (black). Dendrogram shows the result of the
hierarchical clustering calculation for the glycogene expression. (C) Normalized expression of GBGT1 and NAGA; Mean ± SD (three independent
experiments) in the presented cell lines. A high ΔCq value indicates low level of normalized gene expression. (D) Western blot analysis
(autoradiograph and corresponding quantitative analysis) showing GBGT1 protein expression in the presented cell lines (actin is the sample
loading control).
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ter among the cell lines, being expressed at low levels
in ovarian cancer cells (except OVCAR3) and at high
levels in normal ovarian surface epithelial cells.
The preferential expression of GBGT1 in ovarian can-
cer cell lines was fully confirmed in an additional set of
independent experiments (Figure 1C). These results
showed that GBGT1 expression is significantly different
among the tested cell lines (P < 0.001). GBGT1 expression
is high (indicated by low ΔCqmean ±ΔCqSD values) in both
HOSE cells (ΔCqHOSE6–3 = 9.07 ± 0.52; ΔCqHOSE17–1 =
8.55 ± 0.55) and in OVCAR3 cells (ΔCqOVCAR3 = 7.88 ±
0.70) and low in A2780 cells (ΔCqA2780 = 15.41 ± 0.62),
showing that GBGT1 expression is 185-times (ΔΔCq)
lower in A2780 cells than in OVCAR3 cells. Thecomparison of the two normal cell lines (HOSE6-3 and
HOSE17-1) with the panel of ovarian cancer cell lines
(TOV112D, TOV21G, SKOV3, OVCAR3, IGROV1 and
A2780) revealed a significantly differential GBGT1
expression (P < 0.001). In contrast to GBGT1, NAGA
(encodes the alpha-N-acetylgalactosaminidase that hy-
drolyses Fs pentasaccharide) was not differentially
expressed among the cell lines. Western blot analysis
and densitometry data (Figure 1D) demonstrated that
HOSE6-3, HOSE17-1 and OVCAR3 cells display higher
levels of GBGT1 protein than A2780, TOV112D,
TOV21G, and IGROV1 cells. These data were (apart
from SKOV3 showing high GBGT1 protein level despite
low mRNA levels) largely consistent with the RT-qPCR
data.
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DNA methylation
We next investigated whether the observed differential
expression levels of GBGT1 among cell lines correlated
with the DNA methylation status of its CpG island pro-
moter region. Combined bisulfite and restriction analysis
(COBRA) was performed to determine the methylation
status within a 217 bp fragment of the CpG island lo-
cated on chromosome 9: 136038417–136039577. This
CpG island contains 105 individual CpG sites spanning
1161 bp, according to the UCSC Genome Bioinformatics
data base (www.genome.ucsc.edu). The targeted gen-
omic DNA sequence for the COBRA assay is located
within the CpG island from position +28 bp to +245 bp
downstream from the transcription start site (+1 bp)
(Figure 2A). The results showed substantial levels of
DNA methylation in the three investigated CpG sites in
TOV112D, TOV21G, and A2780 cells (Figure 2B), con-
sistent with the qPCR and protein data showing signifi-
cantly reduced GBGT1 expression (Figure 1C, D). InA C
B
Figure 2 DNA methylation of GBGT1 promoter region. (A) Illustration o
start site of the GBGT1 gene. The horizontal black line represents the 217 b
lines represent the organization of individual CpG dinucleotides within the
sites of the restriction endonucleases (Acil, Pvul and BsaAl). Each of these en
dinucleotide(s) within the enzyme recognition site was methylated in the o
PvuI-active 37 + 180 bp; BsaAI-active 192 + 25 bp). (B) COBRA with each of
considerable variation in the methylation status among the cell lines. The d
digested bands as compared to the upper undigested band) was consisten
profiles of individual CpG sites from single DNA strands derived from bisulf
represent individual CpG sites. Rows represent number of sequenced clone
status (white). (D) Restoration of GBGT1 expression in A2780 induced by tre
in GBGT1 transcription. Left, data are presented as the number of PCR prod
(y-axis) as a function of time (24 h, 48 h, 72 h) after treatment (x-axis). Righ
(E) Western blot (autoradiograph and corresponding quantitative analysis)
function of time after treatment in A2780.contrast, no methylation was found in OVCAR3 and in
both HOSE cells (Figure 2B) which exhibited high
levels of GBGT1 expression. An intermediate level of
methylation was found in SKOV3 and IGROV1 cells
(Figure 2B).
Bisulfite sequencing was performed to quantify the
GBGT1 promoter methylation levels in A2780 (high
level), HOSE17-1 (low level), OVCAR3 (low level), and
SKOV3 (intermediate level), and also to determine the
extent of methylation across the CpG island fragment
within individual DNA strands. Figure 2C showed that
95.8% of all CpGs are methylated in A2780, whereas
only 12.1% were methylated in HOSE17-1 and 9.5% in
OVCAR3 cells. The SKOV3 cell line displayed an inter-
mediate 40% methylation of CpGs, preferentially at the
first 7 CpG sites. Bisulfite sequencing therefore showed
a strong inverse correlation between GBGT1 expression
and DNA methylation (r = −0.86; Pearson correlation),
indicating that the majority of ovarian cancer cells have
silenced GBGT1 expression through DNA methylation.D
E
f the organization of the CpG island encompassing the transcription
p amplicon generated using COBRA and bisulfite sequencing. Vertical
amplified region. Black triangles indicate the respective recognition
zymes digested the amplicon only when the respective CpG
riginal DNA prior to bisulfite conversion (AciI-active 50 + 176 bp;
the three different endonucleases (Acil, Pvul, BsaAl) revealed
egree of methylation (which relates to the intensity of the lower
t between each restriction enzyme for each cell line. (C) Methylation
ite sequencing in A2780, HOSE17-1, OVCAR3, and SKOV3. Columns
s (n = 12). Methylated CpG (black), unmethylated (grey), unknown
atment with 2.5 μM 5-Aza. RT-qPCR shows a time-dependent increase
ucts in 5-Aza treated samples relative to the mock-treated control
t, RT-qPCR products of GBGT1 and normalization control YWHAZ.
showing 5-Aza -induced increase in GBGT1 protein expression as a
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deoxycytidine treatment
We determined whether silenced GBGT1 expression in
A2780 cells (95.8% methylation) can be reversed by 5-
aza-2’-deoxycytidine (5-Aza) treatment. 5-Aza is a DNA
methyltransferase inhibitor that de-methylates the DNA
and therefore reactivates or enhances the transcription
of genes suppressed by DNA methylation [19]. We
found that 5-Aza produced a 15-fold increase in GBGT1
expression after 48 h and a 46-fold increase after 72 h in
A2780 cells (Figure 2D), which is also reflected on the
GBGT1 protein level (Figure 2E). A 5-Aza-induced ef-
fect was also observed for SKOV3 cells (40% methyla-
tion) though to a lesser extent (data not shown).
Elevated HPA-staining in A2780 cells after 5-aza-2’-
deoxycytidine treatment
In order to determine whether the 5-Aza-induced in-
crease in GBGT1 expression results in elevated presence
of Fs antigen on A2780 cells we used HPA (Helix poma-
tia agglutinin)-staining as a “surrogate marker” for Fs
antigen. HPA is a lectin which preferentially binds the
Fsdi disaccharide [20], the terminal structure of the Fs
antigen pentasaccharide. Flow cytometry analysis data
showed increased HPA-staining in 5-Aza treated A2780
cells (48 h p = 0.25; 72 h p = 0.08; student t test; Figure 3)
which reflects the elevated presence of Fs on these cells.
Differential DNA methylation of GBGT1 in ovarian tumor
and normal adjacent tissue (analysis of The Cancer
Genome Atlas (TCGA) data)
We wondered whether the observed differential GBGT1
methylation pattern, i.e. largely unmethylated GBGT1 in
the normal HOSE cells and hypermethylated in ovarian
cancer cells, was also found in primary and recurrent
ovarian carcinoma and in normal adjacent tissue. To this
aim we analyzed the methylation levels of GBGT1 using
the publicly accessible data from The Cancer GenomeA
Figure 3 Elevated HPA-staining in A2780 cells treated with 5-Aza. (A)
showing a rightwards peak shift (black solid line) after 48 h and 72 h of 5-Aza-tr
shown by the dashed line. (B) Plot illustrates the increase in HPA-staining man
to the mock controls as a function of time after 5-Aza -treatment. Data prAtlas (TCGA) ovarian cancer sample set [21]. DNA
methylation at two CpG sites within the GBGT1 CpG is-
land promoter, cg18089000 (located 403 bp upstream of
the GBGT1 transcription start site,) and cg01169778 (lo-
cated 613 bp downstream of it), were represented on the
Illumina Infinium HumanMethylation27 BeadChip array
(27 k array). Methylation between these two sites was sig-
nificantly correlated within primary tumor data (n = 528,
Spearman rho = 0.32, P = 1.352e-15). Within the TCGA
ovarian tissue dataset, DNA methylation data for normal
adjacent ovarian tissue were available for a small number
(n = 10) of individuals, of which only four had matched
tumor. The levels of DNA methylation in ovarian tumors
from the TCGA dataset varied widely, which was consist-
ent with our findings in the ovarian cancer cell lines.
GBGT1 methylation levels at both cg01169778 and
cg18089000 in adjacent normal ovarian tissues were con-
sistently high (Figure 4A,B). When all normal samples
(n = 10) were compared with all primary tumors samples
(n = 528), no significant difference in methylation at either
cg01169778 (P = 0.5694) or cg18089000 (P = 0.1136) was
found (Figure 4A,B). However, across individuals for
which paired tumor and normal-adjacent tissue methyla-
tion data was available, cg01169778 was higher in tumors
compared with normal adjacent tissue in all four individuals
(mean difference = 19.1% between tumors and normal adja-
cent) and this difference was borderline statistically signifi-
cant (P = 0.056) (Figure 4C). Methylation of cg18089000
was not significantly different between these four matched
normal and tumor pairs (P = 0.43).
Association between DNA methylation and expression
We now investigated the dependence of GBGT1 expres-
sion on DNA methylation in tissue samples to translate
our cell line-based findings.
Integrated analysis of GBGT1 DNA methylation and
gene expression in the TCGA ovarian cancer data set
showed that DNA methylation at cg18089000 wasB
Flow cytometry data (representative of three independent experiments)
eatment relative to the mock control (grey line). The unstained control is
ifested as the increase in the mean fluorescence intensity (MFI) relative
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Figure 4 GBGT1 methylation and RNA expression levels in The Cancer Genome Atlas (TCGA) ovarian cancer data. Methylation levels
within the GBGT1 CpG island, detected at the (A) cg01169778 and (B) cg18089000 probes on the Illumina Infinium HumanMethylation27
BeadChip array in normal-adjacent ovarian tissue (n = 10), primary ovarian tumor (n = 528) and recurrent tumor (n = 33), do not show a difference
among these three groups. (C) Box-plot showing a borderline significant difference in methylation between matched normal adjacent tissue and
primary tumor pairs (n = 4 cases). (D) GBGT1 RNA expression, determined by the Illumina HiSeq RNA-Seq platform, stratified by GBGT1 methylation
levels at the cg18089000 probe divided into quartiles, (n = Q1(lowest):67, Q2:64, Q3:64, Q4:70). (E) GBGT1 gene expression, determined by the
Huex-1_0-st-V2 Affymetrix exon array, stratified by quartiles of methylation levels at the GBGT1 cg18089000 probe (n = Q1:141, Q2:145, Q3:144,
Q4:141). **P-value (linear regression) <0.01, ***P < 0.001.
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mors, measured using either the Huex-1_0-st-V2 Affyme-
trix exon array (n = 583, rho = −0.27, P = 1.869e-11), or the
Illumina HiSeq RNA-Seq platform (n = 265, rho = −0.42,
P = 1.312e-12) (Additional file 1: Table S1). GBGT1
cg18089000 methylation was not significantly correlated
with GBGT1 exon expression in normal adjacent tissue
(n = 10, Spearman rho = 0.55, P = 0.10) in this small
sample size analysis. In linear models adjusted for age at
pathological diagnosis and clinical stage, cg18089000
methylation was significantly associated with GBGT1
expression, measured by the exon array (n = 571, P =0.0005), and RNA-seq data (n = 265, P = 2.05e-05). A
dose-effect relationship between cg18089000 methylation
and gene expression is apparent when GBGT1 expression
is stratified by DNA methylation quartiles (Figure 4D,E).
In contrast, cg01169778 methylation did not significantly
correlate with GBGT1 expression or associate in linear
models in any sample type using either gene expression
measurement (Additional file 1: Table S1).
Discussion
The present study shows that (i) GBGT1 is the most differ-
entially expressed glycogene involved in the biosynthesis of
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through DNA hypermethylation in ovarian cancer cells and
tissue but re-activated by 5-Aza treatment. In contrast
GBGT1 (iii) does not correlate with clinical outcome (sur-
vival) in ovarian cancer patients. We therefore conclude
that GBGT1 expression is epigenetically regulated in ovar-
ian cancer but that it is not a prognostic predictor for
survival.
The major finding from the present study is DNA
methylation is one mechanism by which GBGT1 expres-
sion is regulated in both ovarian cancer cells and tissue.
This is a novel finding and expands on a previous study
reporting that GBGT1 is differentially methylated and
associated with inflammatory bowel disease [3]. DNA
methylation is one out of at least four epigenetic mecha-
nisms by which eukaryotic organisms regulate the tran-
scription of a significant number of genes, and aberrant
hypermethylation of CpG island promoters associated
with transcriptional silencing is a frequent occurrence in
various types of cancer [22]. Epigenetic silencing is, how-
ever, only one mechanism by which GBGT1 expression
is regulated. GBGT1 nonsense and inactivating missense
mutations have been identified that produce a truncated
or enzymatically inactive protein [4].
Interestingly, a correlation between GBGT1 repression
and DNA hypermethylation was notably not only found
in ovarian cancer cell lines. A bioinformatical analysis of
the Ovarian TCGA dataset showed a clear-cut inverse
correlation between the degree of methylation at the
probe closest to the transcription start site and GBGT1
mRNA expression levels within the TCGA primary ovar-
ian cancers, although the degree of GBGT1 methylation
varied considerably among samples (ranging from nearly
unmethylated to hypermethylated) and levels of GBGT1
methylation were also detected in adjacent normal ovar-
ian tissue. Notably, however, in the four TCGA cases
with matched tumor and normal adjacent tissues higher
methylation levels were found in tumor samples com-
pared to normal adjacent tissues, being in concordance
with our cell line-based observation. The present study
is therefore not only the first one addressing GBGT1 ex-
pression and its regulation in ovarian cancer but also
suggest that GBGT1 is differentially expressed in cancer
and healthy conditions i.e. lower in ovarian cancer pa-
tients and higher in normal cells. This observation is
consistent with a previous study showing GBGT1 mRNA
expression in various tissues [2].
From a clinical point of view it is interesting whether
GBGT1 methylation and/or expression levels associated
with clinical outcome parameters such as survival and
therefore serve as a prognostic factor. However, our
ovarian cancer TCGA dataset analysis did not reveal an
association between methylation or expression levels
and survival (neither in univariate models nor when age-and stage-adjusted), indicating that GBGT1 methylation
or expression levels are not outcome parameters in ovar-
ian cancer.
GBGT1 is not the only glycosyltransferase-encoding
gene regulated by DNA methylation. B4GALNT2 and
ST3GAL6 have been found to be epigenetically silenced
in colon and gastric cancer cells and shown to be re-
expressed after 5-Aza treatment [23]. Both are involved
in the biosynthesis of the blood group carbohydrate Sda
(GalNAcβ1-4(NeuAcα2-3)Galβ1-4GlcNAc) which is
abundantly present on normal gastrointestinal tract mu-
cosa cells but decreased on gastric cancers [24]. FUT7
has been shown to be differentially methylated in pa-
tients with ulcerative colitis and Crohn's disease [3].
Various genes implicated in the glycosylation of secreted
N-linked glycoproteins may also be epigenetically regu-
late because 5-Aza treated ovarian cancer cells displayed
altered glycosylation of these proteins [25].
Another important finding is that A2780 cells incu-
bated with 5-Aza exhibited an elevated HPA staining.
HPA is a lectin from Helix pomatia agglutinin that pref-
erentially binds Fsdi (GalNAcα1-3GalNAc-R), the ter-
minal disaccharide (the product of GBGT1) of Fs
antigen [20,26,27], and therefore HPA staining may
serve as a “surrogate marker” for Fs antigen expression.
In this case, this finding together with the 5-Aza-
induced increase in GBGT1 expression suggests that the
elevated HPA staining may be a result of the increased
GBGT1 expression and Fs synthesis in these cells. On
the other hand, we cannot exclude that 5-Aza also af-
fects the expression of glycogenes other than GBGT1
that, in turn, produces an “elevated binding” of HPA to
glycan structures other than Fsdi. The latter may explain
the relatively high level of HPA-staining in “mock”-
treated A2780 cells in the respective experiment.
HPA expression has previously been proposed as a de-
terminant for poor prognosis in breast, gastric, and
colon cancer [26,28,29]. Given that elevated HPA stain-
ing is a result of increased GBGT1 expression and that
HPA staining is a determinant for poor prognosis also in
ovarian cancer, we would expect increased GBGT1 ex-
pression in cancer cells. The observation that GBGT1
expression is lower by trend in ovarian cancer does nei-
ther support nor rules out the idea that the HPA-
staining may be a prognostic determinant in ovarian
cancer. Earlier studies have suggested Fs antibody titers
as disease determinants: high Fs autoantibody titers were
found in Graves' disease and Hashimoto's thyroiditis
[30] and low were found in patients with cancer of the
gastrointestinal tract and breast [31].
Conclusions
Our results identify GBGT1 as the most differentially
expressed Fs-biosynthesis-relevant glycogene among the
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methylation at its promoter region is one mechanism by
which GBGT1 expression is regulated on the transcrip-
tional level in ovarian cancer. This mechanism may ex-




The serous ovarian cancer cell lines OVCAR3, SKOV3,
A2780 and IGROV1 were cultured in RPMI 1640 medium,
the endometrioid ovarian cancer cell line TOV112D and
the clear cell ovarian cancer cell line TOV21G in DMEM,
and the (normal) human ovarian surface epithelial cells
HOSE6-3 and HOSE17-1 in 1:1 Medium 199:MCDB 105.
All media (Sigma-Aldrich Pty. Ltd, Castle Hill, Australia)
contained 10% FCS (Sigma-Aldrich Pty. Ltd) and penicillin/
streptomycin (Sigma-Aldrich Pty. Ltd). Cells were cultured
at 37°C in 5% CO2. All cultures were free of mycoplasma
(routinely checked as by qualitative PCR using VenorGeM®
Mycoplasma Detection Kit, Biocene Pty Ltd, Rozelle,
Australia).
RNA and DNA extraction
To examine the expression of the glycogenes and the
reference genes, cell cultures were grown in 6-well plates
(NUNC, Thermo Fisher Scientific, Roskilde, Denmark),
washed twice with DPBS (Invitrogen Pty Ltd, Thornten,
NSW, Australia), and lysed by the addition of lysis buf-
fer directly onto the cells (NucleoSpin RNAII Kit,
Macherey&Nagel, Scientifix, Clayton, VIC, Australia).
Total RNA was extracted according to the manufacturer’s
protocol (NucleoSpin RNAII Kit, Macherey&Nagel). After
the elution of total RNA in 50 μl RNase-free water, RNA
concentration and the ratios for A260/230nm and A260/280nm
were measured (NanoDrop ND-1000, Thermo Fisher Sci-
entific). The integrity of the RNA samples, i.e. the RNA in-
tegrity number (RIN) and 28S/18S rRNA ratio, was
determined by electropherograms (Agilent Bioanalyzer
RNA 6000 Nano).
Genomic DNA was extracted from cell cultures grown
in 6-well plates. Cells were lysed with 250 μl lysis buffer
(20 mM Tris–HCl, 4 mM Na2EDTA, 100 mM NaCl),
followed by the addition of 25 μl of 10% (w/v) sodium
dodecyl sulfate (SDS). The lysate was transferred into an
Eppendorf tube and vigorously vortexed. Then 2.5 μl
Proteinase K (Finnzymes, Genesearch Pty Ltd., Arundal,
Queensland, Australia) was added and protein digestion
was performed for at least 2 h at 55°C. Proteins were
then precipitated by adding 200 μl of 5.3 M NaCl,
followed by centrifugation at 13’000xg for 30 min at 4°C.
The supernatant was transferred to a different tube and
an equal volume of ice-cold isopropanol was added in
order to precipitate the DNA by inverting the tubesseveral times. After centrifugation for 15 min (13’000xg) the
DNA was washed with 70% ethanol and re-centrifuged for
10 min. Genomic DNA was dissolved in 10 mM Tris HCl
pH 8.5 and the DNA concentration was measured with the
NanoDrop ND-1000 (Thermo Fisher Scientific).
All RNA extracts were of high quality and purity: the
RNA integrity number (RIN) was 10, the values for A260/
280 and A260/230 ranged from 2.08-2.16 and 1.80-2.21, re-
spectively, and the 28 s/18 s ratio ranged from 1.9-2.3.
Reverse Transcription (RT) and quantitative Polymerase
Chain Reaction (qPCR)
An amount of 500 ng to 1 μg total RNA was reverse-
transcribed using the iScript Reverse Transcription
Supermix for RT-qPCR according to the manufacturer’s
instructions (Bio-Rad Laboratories (Pacific) Pty Ltd,
Gladesville, Australia). The complementary DNA (cDNA)
was stored at −20°C until further use.
QPCR was performed on the selected glycogenes and
reference genes (HSPCB, SDHA, YWHAZ) in order to in-
vestigate the relative expression of the glycogenes in the
selected cell lines and the patient samples. The variation
of reference genes for normalization (mean coefficient of
variation of 4.75%) reflecting biological and inter-assay
variability was in full concordance with our previous ob-
servation on selected reference genes in Jacob et al. 2013
[32]. A listing of the accession number, the name of the
gene, the sequence of forward and reverse primers, and
the amplicon size is presented in Table 1. The reference
gene primers were selected according to their specificity
to human cDNA and their stable expression pattern. The
‘glyco gene’ primers were designed using QuantPrime [33]
(purchased from Sigma-Aldrich Pty. Ltd). QPCR was per-
formed with Stratagene Mx3005® (Integrated Sciences Pty.
Ltd, Chatswood, Australia) in 96-well microtiter plates
using the 2x SensiFAST™ SYBR Lo-ROX kit (Bioline Pty
Ltd, Alexandria, Australia) with low ROX as the reference
dye. Optimum reaction conditions were obtained with 400
nM specific sense primer, 400 nM specific antisense primer,
RNase/DNase-free water, and cDNA template up to final
volume of 20 μl. QPCR setups were based on 10 ng of the
previously isolated and reverse-transcribed total RNA. Am-
plifications were performed starting with a 30 sec enzyme
activation at 95°C, followed by 40 cycles of denaturation at
95°C for 5 sec, and an annealing/extension step at 60°C for
30 sec. A melt curve was produced from 65-95°C (continu-
ous measurement). All samples including the negative con-
trols were amplified in triplicates. Mean, standard deviation
(SD) and coefficient of variation were calculated. For inter-
assay comparability a 0.1 threshold was set for all runs for
the determination of the Cq values. Quantification cycle
(Cq) values of >36 were excluded from further mathemat-
ical calculations, because Cq > 36 do not represent quanti-
tative information of the cDNA/RNA amount and
Table 1 qPCR primers
Gene Accession number Gene Name Forward Primer 5’-3’ Reverse Primer 5’-3’ Amplicon size in bp
A4GALT NM_017436 α1,4-galactosyl transferase CGCTGGAGCTAGAGATGGATTTGC AGCCGACCTTCTTTGCCAACAC 78
GLA NM_000169 α galactosidase A precursor TCTAATGACCTCCGACACATCAGC ACACTTCAAAGTTGTCTCCCTGTC 130
HEXA NM_000520.4 β hexosaminidase α chain precursor TTTGTCACACTTCCGCTGTGAG ACTCCTGCTCACAGAAGCCTAC 80
GBA NM_001171812 glucosidase, β, acid ACAGCCACAGCATCATCACGAAC TGGGACTGTCGACAAAGTTACGC 117
UGCG NM_003358 UDP-glucose ceramide glucosyltransferase TGTGTTGGATCAAGCAGGAGGAC AACCTCCAACCTCGGTCAGCTATC 96
B4GALT6 NM_004775 UDP-Gal:βGlcNAcβ1,4- galactosyltransferase, polypeptide 6 AGGAGGTCCCTATGGCACTAAC TCTCTACAGACAGGCCCATTAGTC 89
GLB1 NM_001079811 galactosidase, β1, transcript variant 1 TGGCCAGCCATTTCGCTACATC TGAAAGTTCCAGGGCACATACGTC 135
HEXB NM_000521 β-hexosaminidase β chain precursor GCAAGTGCTGTTGGTGAGAGAC GTTGTGCAGCTATTCCACGTTCG 118
GBGT1 NM_021996.4 Globoside α-1,3-N-acetylgalactosaminyltransferase 1 GCACAAGCTTCAGTGTCCTGTG TGGCTTCTCCCTCTTGTAGTGC 122
B3GALNT1 NM_033169 β1,3-N-acetylgalactosaminyl transferase 1 TGCTCTATCACGTGGTGCTCTC ACGCGAGCCGAAGGTTCTTTAC 62
NAGA NM_000262.2 N-acetylgalactosaminidase, α AGCTTCCAGAGCCCAACACATAC ACATGTCCCAGCAAGAGCACTG 113
HSPCB NM_007355 Heat shock protein 90 kDa α TCTGGGTATCGGAAAGCAAGCC GTGCACTTCCTCAGGCATCTTG 80
YWHAZ NM_001135702 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypetide
ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 94
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periments were performed in compliance to MIQE guide-
lines [18].
The qPCR assay performance for each glycogene and
three reference genes (HSPCB, SDHA and YWHAZ) was
determined in four consecutive 10-fold dilution steps.
The value for PCR efficiency ranged from 97.0%
(GBGT1) to 107.3% (HEXA), and the coefficient of deter-
mination (R2) was always higher than 0.995, indicating
that the qPCR assay performance was reliable (Table 2).
An amount of 10 ng RNA was used for each of the gene
transcripts in the profiling experiments.
The ΔCq values for each glycogene, obtained by
normalization against the logarithmic mean of the three
reference genes profiled in parallel, and for each cell line
were subjected to clustering analysis and presented as a
heat map (Figure 1).
Bisulfite conversion and COBRA (Combined Bisulfite
Restriction Analysis)
Bisulfite conversion was performed using the EZ DNA
Methylation-Gold™ Kit according to the manufacturer’s
protocol (ZYMO RESEARCH, Integrated Sciences, Pty.
Ltd, Chatswood, Australia). An amount of 500 ng gen-
omic DNA was used for bisulfite conversion.
Bisulfite converted genomic DNA was subjected to poly-
merase chain reaction (PCR) using Platinum® Taq DNA
Polymerase (Invitrogen Pty. Ltd., Blackburn, Australia).
The primers, designed using MethPrimer [34] (purchased
from Sigma-Aldrich Pty. Ltd., Castle-Hill, Australia). PCR
was set up as follows: 1x Platinum Taq reaction buffer,Table 2 qPCR parameters describing the standard curve
for each primer pair on eleven glycogenes and three
reference genes




UGCG −3.1875 21.58 105.9 0.999 10 ng-100 ng
GBA −3.2175 24.48 104.6 0.998 10 pg-100 ng
B4GALT6* −3.1905 29.01 105.8 0.998 5 pg-50 ng
GLB1 −3.1640 24.29 107.0 0.991 1 pg-10 ng
A4GALT −3.3425 28.63 99.1 0.998 10 pg-100 ng
GLA −3.2025 25.75 105.2 0.998 10 pg-100 ng
B3GALNT1 −3.2425 27.92 103.4 0.999 10 pg-100 ng
HEXA −3.1575 23.92 107.3 0.999 10 pg-100 ng
HEXB −3.2300 22.51 104.0 0.999 10 pg-100 ng
GBGT1 −3.395 32.69 97.0 0.995 100 pg-100 ng
NAGA −3.152 28.36 107.0 0.999 100 pg-100 ng
HSPCB* −3.250 20.09 103.1 0.998 1 pg-100 ng
YWHAZ* −3.294 20.35 101.2 0.998 1 pg-100 ng
SDHA* −3.194 24.64 105.6 0.994 1 pg-100 ng
*Standard curve was established previously [32].1 mM MgCl2, 100 nM dNTP mix, 400 nM forward
(GBGT1_COBRAfor6; 5’-TGT TTG TTT TGT TTT AGG
TTT TAT TTG-3’) and reverse primer (GBGT1_CO-
BRArev6; 5’-AAA ACC CTC CTC CTT AAC CCC TTA
C-3’) and 0.05 units of Taq polymerase made up with Ultra
Pure™ distilled water (Invitrogen Pty. Ltd., Blackburn,
Australia) to a final volume of 20 μl. PCR was performed
by initial denaturation at 94.0°C for 5 min, followed by
40 cycles of 94°C for 30 sec, 58°C for 30 sec, 72°C for
45 sec, and finally by amplicon elongation at 72°C for
10 min. The PCR product (size 217 bp) was visualized in a
1.7% agarose gel. Restriction fragment length analysis was
performed on PCR products incubated with the restriction
endonucleases AciI (methylated 50 bp + 167 bp, unmethy-
lated 217 bp), PvuI-HF (methylated 37 bp + 180 bp,
unmethylated 217 bp) and BsaAI (methylated 192 bp +
25 bp, unmethylated 217 bp) (New England BioLabs Inc.,
Genesearch Pty Ltd., Arundal, Queensland, Australia). Gen-
omic DNA isolated from human blood serum served as an
unmethylated COBRA control. Genomic DNA from the
same sample treated with CpG methyltransferase M.SssI
(New England BioLabs Inc., Genesearch Pty Ltd.) served as
the positive methylation control.
Bisulfite Sequencing
COBRA-based PCR for GBGT1 was performed as de-
scribed above. For subsequent ligation, the PCR prod-
ucts were extracted from the 1.7% agarose gel using the
QIAquick® Gel Extraction Kit (Qiagen Pty Ltd, Doncaster,
VIC, Australia) and ligated into pGEM®-T Easy Vector
System I according to the manufacturer’s protocol (Pro-
mega, Alexandria, NSW, Australia). Afterwards, the entire
ligation was heat shock transformed into E.coli XL10
GOLD strain. Bacterial cells were held together with the
ligation on ice for 30 min, followed by incubation at 42°C
for 35 sec. Immediately after heat shock, bacterial cells
were placed on ice for 2 min and pre-warmed medium
(Sigma-Aldrich Pty. Ltd., Castle-Hill, Australia) was added,
followed by incubation at 37°C for 1 h. Transformed bac-
teria were plated on LB agar plates containing 50 μg/ml
carbenicillin, IPTG, and X-Gal, and were incubated over-
night at 37°C. White colonies were picked and colony
PCR was performed using the T7 universal primer (5’-T
AA TAC GAC TCA CTA TAG GG-3’) and SP6 universal
primer (5’-ATT TAG GTG ACA CTA TAG-3’) (Sigma-
Aldrich Pty) to amplify the plasmid inserts. The conditions
were as follows: 1x Platinum Taq reaction buffer, 3 mM
MgCl2, 100nM dNTP mix, 400nM forward and reverse
primer, and 0.05 units of Taq polymerase made up with
Ultra Pure™ distilled water up to a final volume of 20 μl.
PCR samples were separated on a 1.7% agarose gel. Free
dNTPs were removed by enzymatic PCR clean-up and the
remaining primers were incubated with the PCR products
for 30 min at 37°C with 2.5U Antarctic phosphatase and
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search Pty Ltd., Arundal, QLD, Australia) dissolved in 1×
Antarctic Phosphatase Reaction buffer. The reaction was
heat-inactivated at 80°C for 20 min. The PCR clean-up re-
action was applied to the sequencing reaction, containing
0.5 μl BigDye®, Terminator v3.1 Cycle Sequencing Kit (Ap-
plied Biosystems Australia Pty Ltd, Mulgrave, VIC,
Australia), 2 μl 5× sequencing reaction buffer, 0.35 μl SP6
universal primer, and 2.5 μl distilled water. The sequen-
cing reaction was performed using the following condi-
tions: 94°C for 20 sec, 50°C for 20 sec, and 60°C for 4 min.
All steps were repeated for 25 cycles. DNA was precipi-
tated by 100% ethanol and 3 M sodium acetate pH5.2,
washed with 70% ethanol, and air-dried. Samples were se-
quenced (ABI 3730 Capillary Sequencer, The Ramaciotti
Centre for Gene Functional Analysis, University of New
South Wales, Sydney, NSW, Australia). Bisulfite sequen-
cing data were visualized and analyzed using the web
based software BISMA, Bisulfite Sequencing Data Presen-
tation and Compilation [35].
5-aza-2’-deoxycytidine treatment
Cells carrying a hypermethylated GBGT1 gene were
treated with 5-Aza (Sigma-Aldrich Pty. Ltd; stock solution
prepared in 50% (v/v) acetic acid) in order to restore or in-
crease GBGT1 expression. An amount of 105 cells were
seeded in 6-well plates (NUNC, Thermo Fisher Scientific
Pty. Ltd., Scoresby, Australia) and treated with 5-Aza
(2.5 μM final concentration) on the next day. The culture
medium was removed every 24 h and replaced by fresh
culture medium containing 2.5 μM 5-Aza. Samples were
harvested after 24 h, 48 h and 72 h of treatment. Genomic
DNA and total RNA were extracted as described above.
Mock controls contained 50% (v/v) acetic acid at concen-
trations identical to 5-Aza.
Preparation of cell lysates and Western blot analysis
Whole cell lysates were obtained from subconfluent cul-
tures. The cultures were treated with 5-Aza or a corre-
sponding concentration of acetic acid (mock control)
24 hours after seeding. Cells were then harvested 48 h
or 72 h after treatment. Cells were lysed for Western
blot analysis according to standard laboratory protocols.
The protein concentration of cell lysates was deter-
mined by the BCA Protein Assay Kit (Pierce, Perbio Sci-
ence, Lausanne, Switzerland). Twenty μg protein was
loaded and separated using SDS-PAGE, followed by
blotting onto a polyvinylidene difluoride membrane
(Amersham Biosciences, Otelfingen, Switzerland). Pro-
teins were detected with specific primary antibodies
(goat anti-GBGT1, Lab Force, Nunningen, Switzerland;
anti-mouse β-actin, Sigma-Aldrich, Buchs, Switzerland;
anti-rabbit tubulin, Cell Signaling, BioConcept, Allschwil,
Switzerland) and the appropriate horseradish peroxidase-conjugated secondary antibodies (anti-goat IgG-HRP, Lab
Force, Basel, Switzerland; anti-rabbit IgG-HRP and
anti-mouse IgG-HRP, Cell Signaling, BioConcept, Basel,
Switzerland). Complexes were visualized by enhanced
chemiluminescence (Amersham Biosciences, Otelfingen,
Switzerland) and autoradiography. Densitometry (quanti-
tative analysis of the intensity of the complexes on the
autoradiograph, normalized against actin orv tubulin) was
performed using the XXXXX software.
Flow cytometry analysis
The presence of Fsdi on the cell membrane was analyzed
by flow cytometry (BD Accuri C6 flow cytometer, BD
Bioscience, Basel, Switzerland). Biotin-conjugated helix
pomatia agglutinin (HPA; Sigma-Aldrich Pty. Ltd.,
Castle-Hill, Australia) followed by streptavidin conju-
gated to FITC (BD Bioscience, Basel, Switzerland) was
used for fluorescence detection. Single cells were gated
to quantify HPA-positive cells (cell debris excluded).
Data acquisition was performed using BD Accuri C6
software (BD Bioscience, Basel, Switzerland). Data ana-
lysis was performed using the FlowJo v10 software (Tree
Star Inc., Ashland, USA).
TCGA clinical sample data analyses
The Cancer Genome Atlas ovarian cancer molecular and
clinical data was downloaded from the Broad Institute
TCGA Data and Analysis website (https://confluence.
broadinstitute.org/display/GDAC/Home) which pro-
vides data subjected to standardized preprocessing and
normalization, as described in detail on their website.
DNA methylation was measured using the Illumina Infi-
nium HumanMethylation27 BeadChip array (n = 582 pri-
mary ovarian tumor sample, 10 normal adjacent tissue
samples and 18 recurrent tumor samples). GBGT1 expres-
sion was measured using the Huex-1_0-st-V2 exon array
(n = 583 primary tumors overlapping with DNA methyla-
tion data) and Illumina HiSeq RNA-Seq (n = 265 primary
tumors overlapping with DNA methylation data) plat-
forms. Technical analysis parameters were as described on
the TCGA website (http://cancergenome.nih.gov/).
Statistical analysis
Basic R packages and R package ‘qPCR’ [36] from the open
source statistical programming language R (http://CRAN.
R-project.org/, version 2.13.2) were used for data analysis of
qPCR (including the calculations of PCR efficiency, slope,
intercept and r squared (r2)). The one-way ANOVA test
with a significance level of P < 0.01 was applied to compare
gene expression among the cell lines. Student’s t test was
applied to compare gene expression levels between normal
and cancer cell lines. Pearson correlation (R package “stats”)
was performed for the relationship between RT-qPCR data
and bisulfite sequencing data.
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to test for normal distribution within molecular data. DNA
methylation deviated significantly from a normal distribu-
tion at GBGT1 cg01169778 (P < 2.2e-16) and cg18089000
(P < 2.2e-16), and RNA-Seq data for GBGT1 was not nor-
mally distributed (Shapiro Wilks P = 8.538e-16), therefore
data for these variables were log-transformed for all para-
metric tests, whereas exon array data, which was not abnor-
mally distributed (P = 0.09), was not log transformed.
Spearman correlations were used to test for correlations be-
tween DNA methylation and gene expression, and linear
regression was used to test for associations between methy-
lation and expression, adjusting for other variables, with
methylation treated either as a continuous variable or as a
categorical variable based on methylation quartiles. The
Student’s t-test was used to test for DNA methylation dif-
ferences between tumor and adjacent normal tissue, with
matching for matched pairs. Cox proportional hazard
models were used to test for associations between DNA
methylation (or gene expression) and survival time, mea-
sured as days until death from pathological diagnosis, with
methylation treated either as a continuous variable or as a
categorical variable based on methylation quartiles. Cox
models were adjusted for age at pathological diagnosis and
clinical stage, as these factors were significantly associated
with survival time (age: P = 0.0007, HR = 1.02, stage: P =
0.0008, HR = 1.3). Kaplan-Meier plots were used to visually
compare survival time differences between DNA methyla-
tion categories.Additional file
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